Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ribociclib + Letrozole OR Fulvestrant|DRUG: Palbociclib + Letrozole OR Fulvestrant|DRUG: Paclitaxel +/- Tislelizumab
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Novartis|Alliance Foundation Trials, LLC.